Drug Price Trends for NDC 60505-3847

Average Pharmacy Cost for 60505-3847

Drug Name	NDC	Price/Unit ($)	Unit	Date
CELECOXIB 50 MG CAPSULE	60505-3847-06	0.10369	EACH	2026-03-18
CELECOXIB 50 MG CAPSULE	60505-3847-06	0.10373	EACH	2026-02-18
CELECOXIB 50 MG CAPSULE	60505-3847-06	0.10496	EACH	2026-01-21
CELECOXIB 50 MG CAPSULE	60505-3847-06	0.09522	EACH	2025-12-17

Best Wholesale Price for NDC 60505-3847

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
CELECOXIB 50MG CAP	Golden State Medical Supply, Inc.	60505-3847-06	60	6.66	0.11100	2023-06-16 - 2028-06-14	FSS

Market Analysis and Price Projections for Drug NDC 60505-3847

Last updated: February 16, 2026

Overview

NDC 60505-3847 is registered as Xenazine (tetrabenazine). It is used primarily for Huntington’s disease-associated chorea. The drug is marketed by Teva Pharmaceuticals. The market dynamics and pricing trends for tetrabenazine-related formulations provide insight into future pricing and market share expectations.

Market Size

• Patient Population: Huntington's disease affects approximately 3-7 per 100,000 people in the United States. The active user base for tetrabenazine is estimated at 8,000–10,000 patients, considering off-label use and treatment practices.

• Sales Data: In 2022, Xenazine generated approximately $200 million in U.S. sales (IQVIA data). Global sales include extrapolated revenues from other markets, primarily Europe and Asia.

• Competitive Landscape:

  • Deutetrabenazine (Austedo): Approved for chorea in Huntington’s and tardive dyskinesia; sales in 2022 reached $580 million globally.
  • Valbenazine (Ingrezza): Also for tardive dyskinesia; global sales approximately $950 million in 2022.

Market Drivers

• Expansion of indications, such as for tardive dyskinesia, increases potential patient pool.
• Increasing diagnosis and awareness of Huntington’s disease, although incidence remains low.
• Prescriber preference shifts toward newer agents with improved side-effect profiles.

Pricing Trends and Projections

• Current Pricing:

  • Average Wholesale Price (AWP)/unit: Approximately $7 to $9 per 25 mg tablet.
  • Per Month Cost: A typical dose of 25 mg three times daily results in roughly $630 to $810 per month.
  • Patient Cost: Insurance coverage often reduces direct costs, but out-of-pocket expenses remain significant.

• Historical Trends:

  • Since patent expiration, price reductions have been minimal.
  • Market entry of generic tetrabenazine formulations reduces average prices, but Teva’s branded version commands a premium due to formulation stability and provider trust.

• Future Price Projection (Next 5 Years):

  • Price Stability: Given the small patient population and the low competition, prices are expected to remain relatively stable.
  • Potential Price Reduction: Emergence of new generic formulations could push prices downward by 10–15% over the next two years.
  • Impact of New Formulations: Novel delivery methods or extended-release versions could command higher prices initially, but market penetration would depend on efficacy and reimbursement policies.

Regulatory and Reimbursement Context

• The U.S. CMS and private payers often reimburse branded tetrabenazine at rates similar to generics, but formulary preferences dictate access.
• Price negotiations may influence capsule procurement costs, especially as generic options increase.

Market Outlook

• The niche market size constrains aggressive price discounts.
• Growth in off-label use presents limited upside due to regulatory constraints.
• Competition with Deutetrabenazine and Valbenazine fragments the market share but does not substantially threaten Teva’s dominant position.

Key Data Summary

Aspect	Details
Estimated U.S. patient base	8,000–10,000 patients
2022 U.S. sales	Approximately $200 million
Current unit price	$7–$9 per 25 mg tablet
Monthly treatment cost	$630–$810 for typical dosing
Price projection (2–5 years)	Stability with potential 10–15% reduction post-generic entry

Summary

The market for NDC 60505-3847 remains stable with limited growth prospects due to the small patient population. Prices are expected to stay within the current range, with a slight decline likely over the next two years as generic competition increases. Pricing will remain influenced by formulary decisions, reimbursement policies, and the advent of new formulations.

---

Key Takeaways

• The tetrabenazine market is limited but stable, with significant branded price premiums.
• Competition and generic entries are poised to exert downward pressure, but prices will likely remain above $7 per tablet.
• Market growth relies on increasing diagnosis and new indications, but overall size remains constrained.
• Reimbursement policies and formulary preferences greatly affect net prices.
• Innovations in drug delivery or formulation could temporarily elevate pricing but will depend on regulatory approval and market acceptance.

---

FAQs

1. What is the primary indication for NDC 60505-3847?
   Huntington’s disease-associated chorea.

2. How does generic entry affect tetrabenazine prices?
   It typically leads to a 10–15% price reduction within two years, depending on market share and competitive offerings.

3. Are there any approved alternatives that threaten this drug's market share?
   Yes, deutetrabenazine (Austedo) and valbenazine (Ingrezza) are approved for similar indications and command larger global sales.

4. What factors influence the future price of this drug?
   Generic competition, formulation innovations, regulatory changes, and payer reimbursement policies.

5. How does the small patient population impact pricing strategies?
   It limits volume but supports higher per-unit pricing to recover development and manufacturing costs, keeping prices relatively stable.

---

References

[1] IQVIA. "2022 Prescription Data."
[2] FDA. "Approved Drugs for Huntington’s Disease."
[3] Teva Pharmaceuticals. "Xenazine Product Label."
[4] MarketWatch. "Global hemophilia therapy market size estimates."
[5] CMS. "Reimbursement policies for rare disease treatments."